Your Kidneys on GLP-1: What the FLOW Trial Found (and What It Means for You)

When a data safety monitoring board halts a clinical trial early, it usually means something went wrong — people got hurt, the drug did something nobody expected, and the whole thing gets shut down to stop the bleeding.

The FLOW trial — semaglutide versus placebo in adults with type 2 diabetes and chronic kidney disease — stopped early too. But for the opposite reason.

It stopped because the results were so lopsided in favor of semaglutide that keeping half the participants on placebo stopped being ethical. At a median of 3.4 years into a trial designed to run longer, the monitoring board looked at the numbers and called it. Enough. We know.

So what did they know? That semaglutide 1.0 mg weekly — the Ozempic dose, not the higher Wegovy dose — cut the risk of major kidney disease events by 24% compared to placebo. The full results landed in the New England Journal of Medicine in May 2024. If you have type 2 diabetes and CKD, these are numbers worth sitting with.

What "major kidney disease events" actually means

FLOW didn't chase vague outcomes. The primary endpoint was a composite of four specific, hard events: a sustained drop of 50% or more in eGFR (a key measure of how well your kidneys filter), a sustained eGFR below 15 (kidney failure territory), starting dialysis or getting a kidney transplant, or dying from kidney or cardiovascular causes.

None of those are soft. They're the exact things nephrologists and patients spend years trying to outrun. The trial enrolled 3,533 adults with both type 2 diabetes and CKD — defined as an eGFR between 25 and 75 mL/min/1.73m² — a range that covers everyone from modestly reduced kidney function to the doorstep of end-stage disease.

The hazard ratio came back at 0.76, with a 95% confidence interval of 0.66 to 0.88, and a p-value below 0.001. That is not a borderline result. The confidence interval doesn't even flirt with 1.0.

The trial also tracked eGFR decline over time, beyond the headline event count. In the semaglutide group, the rate of kidney function decline slowed by approximately 1.16 mL/min/1.73m² per year compared to placebo. In isolation that sounds tiny. But kidney function doesn't grow back — once it's gone, it's gone — so slowing the rate of decline is the whole ballgame.

The FLOW trial results at a glance

The weight loss number deserves a quick footnote: this was the 1.0 mg Ozempic dose in a T2D+CKD population, not the higher-dose obesity trials. So the weight difference versus placebo was modest — roughly 3–4 kg (about 4–5% of body weight) — not the double-digit drops you see with semaglutide 2.4 mg. Which prompts a fair question: how much of the kidney benefit is just better weight and glucose control? Probably some of it. But the trial and the mechanistic research both point to something extra going on, and that's exactly what the next section is for.

How GLP-1s may protect the kidneys

Short version: it's probably several mechanisms hitting at once, not one clean pathway.

Blood sugar control is the oldest part of the story. Chronically high glucose chews up the tiny blood vessels inside the kidney's filtering units (the glomeruli) — a process called glycotoxicity. GLP-1 receptor agonists lower blood sugar, which is their original FDA-approved reason to exist, so some kidney protection follows naturally from better glucose management.

Blood pressure is the second piece. Lower pressure means less mechanical stress on the glomeruli, which slows the progressive scarring that CKD patients spend years fighting. Semaglutide modestly reduces blood pressure, and every millimeter counts when the kidneys are already under strain.

Then there's weight. Excess weight raises intraglomerular pressure — the pressure inside the kidney's tiny filters — independently of blood sugar. So even the modest weight loss seen in FLOW (~3–4 kg vs placebo) matters for the kidneys on its own terms, not just as a proxy for general health.

Here's where it gets more interesting. GLP-1 receptors actually live in kidney tissue — they've been found in the proximal tubule cells and in mesangial cells. That opens the door to direct anti-inflammatory and antioxidant effects, separate from anything happening with weight, blood sugar, or blood pressure. Researchers are still untangling exactly how those direct effects play out, but the receptors themselves are an established fact. Something is happening locally, not just systemically.

Albuminuria — protein leaking into the urine, a marker of kidney damage — also dropped in the semaglutide arm of FLOW. It's a secondary finding, but albuminuria reduction has historically predicted slower progression to kidney failure, and it lines up neatly with the primary endpoint data.

Put it together and you get a stack of overlapping mechanisms:

1. Blood sugar control (reduces glycotoxicity)
2. Blood pressure reduction (reduces glomerular mechanical stress)
3. Weight loss (lowers intraglomerular pressure)
4. Direct anti-inflammatory effects via kidney GLP-1 receptors
5. Reduced albuminuria (less protein leaking through damaged filters)
6. Reduced oxidative stress (cellular-level damage control)

The SGLT2 inhibitor question — because your nephrologist will bring it up

If you have CKD and you're sitting across from a kidney specialist in 2026, you've almost certainly heard about SGLT2 inhibitors. Dapagliflozin (Farxiga) and empagliflozin (Jardiance) both carry FDA-approved CKD indications. This isn't off-label for kidney disease — it's formally, on-the-label approved. The DAPA-CKD trial (dapagliflozin, 2020) showed a 39% reduction in kidney disease progression or death among people with CKD, including those without diabetes. CREDENCE (canagliflozin) and EMPA-KIDNEY (empagliflozin) piled on more supporting data over the same stretch of years.

This is the current standard of care. SGLT2 inhibitors got there first, hold the clearest regulatory approval, and are what most nephrologists reach for before anything else.

The FLOW data for semaglutide doesn't erase any of that — it adds to it. The question buzzing at nephrology conferences right now isn't "SGLT2i or GLP-1?" It's "should high-risk patients be on both?" Early combination data is starting to come in. The two drug classes work through largely different mechanisms, so there's a real chance they stack rather than overlap.

If your nephrologist hasn't already raised SGLT2 inhibitors for your CKD, bring them up by name. The FLOW data for semaglutide is compelling, but SGLT2i approval came first, and that's where most kidney-specific conversations should start.

About 850 million people have CKD — and most don't know it

Chronic kidney disease affects roughly 850 million people globally. In the United States, about 37 million adults — around 15% of the adult population — have CKD. Most of them have no idea. Kidney disease is famously quiet until it isn't: eGFR can slide for years with zero symptoms, and by the time people feel sick, the damage is already deep.

Diabetic kidney disease is the number one cause of end-stage renal disease (ESRD) worldwide. In the US, diabetes drives about 38% of new ESRD cases every year. That's why FLOW is such a loaded result. The overlap between type 2 diabetes and CKD is enormous, the road to dialysis or transplant is brutal and expensive, and any drug that slows that road down has outsized population-level impact.

It helps to picture what dialysis actually is. Three to four sessions a week, each one running three to five hours. A chair, a needle in your fistula arm, a hum from the machine, and a TV bracketed to the wall playing daytime cable. Strict fluid and dietary limits. A sharp jump in cardiovascular mortality. Average life expectancy on dialysis in the US runs 5–10 years. The whole point of treatment is to delay it, or skip it. A 24% reduction in the events that lead there is not a footnote.

The realistic picture — no approval yet, cost barriers are real

No sugarcoating this part. As of May 2026, no GLP-1 medication has FDA approval for chronic kidney disease. Not semaglutide, not tirzepatide, not any of them. The FLOW data is Phase 3 and published in the NEJM — the caliber of evidence that usually backs an FDA filing — but Novo Nordisk hasn't landed a CKD indication yet.

In practice, here's what that means. If you and your doctor decide semaglutide makes sense for your kidneys, you're in off-label territory. Your doctor can absolutely do this — it's legal, and physicians prescribe off-label constantly — but the insurance side gets messy fast.

Ozempic is usually covered when diabetes is the diagnosis. If your plan covers it for T2D and you happen to have CKD too, the kidney benefit rides along, so to speak. But trying to get GLP-1 coverage by citing CKD as the indication is a much harder conversation with your insurer, and prior authorization denials are common.

On cost: Ozempic lists at roughly $900–$1,000 a month without insurance. Wegovy runs around $1,349. With no coverage, that's the number staring back at you. Medicare has been widening GLP-1 coverage for cardiovascular and obesity indications — changes taking effect in mid-2026 — but CKD isn't part of that expansion yet.

GoodRx and NovoCare (Novo Nordisk's patient assistance program) can bring costs down meaningfully for people who qualify. The eligibility thresholds shift around, so it's worth checking directly instead of assuming you're out of luck.

If you're waiting for full FDA approval before bringing this up with your doctor, you might wait years. The data is out there now. Showing your nephrologist or endocrinologist the FLOW trial and asking "does this apply to me?" is a reasonable thing to do at your next appointment.

What to check before starting — the practical list

Before semaglutide makes sense for someone with CKD, a handful of baseline numbers matter.

eGFR (estimated glomerular filtration rate): This is your kidney function score. FLOW enrolled people with eGFR 25–75. If yours is below 15, you're in kidney failure territory, and the prescribing conversation changes shape entirely. If it's above 60, your CKD is early-stage and the urgency may be lower. The number that really matters is where you sit on the slope — how fast is your eGFR dropping year over year?

UACR (urine albumin-to-creatinine ratio): This measures how much protein is leaking into your urine, which tells you how damaged your kidney filters are. Above 30 mg/g is abnormal; above 300 mg/g lands you in the high-risk zone. Semaglutide reduced albuminuria in FLOW, so knowing your baseline UACR gives you and your doctor a way to track the drug's kidney effects over time.

Current CKD medications: Are you already on an SGLT2 inhibitor (Farxiga, Jardiance)? An ACE inhibitor or ARB for blood pressure? Your nephrologist will want to see the full picture before adding a GLP-1.

HbA1c and blood sugar control: FLOW required T2D enrollment. If your diabetes is poorly controlled, that's the primary argument for semaglutide, and the kidney benefit is additive.

Blood pressure: Both elevated BP and the blood pressure reduction from semaglutide matter. If you're already on multiple antihypertensives, adding a drug that further lowers BP requires monitoring.

Insurance and formulary status: Before you get attached to a treatment plan, find out where semaglutide sits on your plan's formulary. A quick call to your insurance's pharmacy benefits line — or a peek through your patient portal — will tell you what tier it's on and whether a prior authorization is in your future.

Questions to bring to your doctor

These are specific, not generic. The goal is a conversation, not a pamphlet.

• "My eGFR has been declining at roughly X points per year. Given the FLOW trial data, does adding semaglutide make sense for slowing that progression?"
• "I'm currently on [SGLT2i/ACE inhibitor/ARB]. Is there evidence supporting combining any of those with semaglutide for CKD?"
• "What UACR level should I aim for, and would you re-check it after three to six months on semaglutide to see if it's moving?"
• "Would you prescribe semaglutide off-label for kidney protection, or do we need to wait for an FDA CKD indication? What's your read on the FLOW data?"
• "My insurance requires prior authorization for Ozempic. Can we list type 2 diabetes as the primary indication and document CKD as a secondary motivation?"
• "What are the signs that semaglutide isn't working well for my kidneys, and what would trigger a change in plan?"
• "Is there any reason my level of CKD would make the nausea side effects harder to manage?" (Kidney function affects drug clearance, and that's worth asking about directly.)

For people who have watched their kidney numbers slide for years, FLOW was the first trial that pointed to a drug that might slow the decline itself rather than just manage the symptoms around it.

The SELECT trial adds another data point

FLOW was the headliner for kidney disease, but it wasn't the only trial watching semaglutide's kidney effects. The SELECT trial — which tested semaglutide 2.4 mg (the Wegovy dose) in people with obesity and established cardiovascular disease, but without diabetes — also tracked kidney function as a secondary endpoint. eGFR declined more slowly in the semaglutide group than in placebo, even in people without diabetes.

That stretches the FLOW story in a meaningful way. FLOW showed kidney protection in people with type 2 diabetes and CKD. SELECT hints that the kidney signal might be there in people with obesity alone — no diabetes required. It wasn't the primary endpoint of that trial, and it shouldn't be read as equal to FLOW's primary evidence, but it points the same direction.

The full picture of who benefits most from GLP-1 kidney protection is still being drawn. Phase 3 data in non-diabetic CKD populations would close a lot of open questions.

This fits a pattern — GLP-1s keep turning up in unexpected places

If you've been following the GLP-1 research over the past three years, the kidney data fits a pattern. These drugs were approved for blood sugar control. Then weight loss. Then cardiovascular risk reduction (the SOUL trial and related CV data showed a 14% reduction in major cardiac events, HR 0.86). Then fatty liver disease data — three separate NEJM papers in 2024. And now kidneys.

The thread running through all of it: GLP-1 receptors aren't just in the pancreas and brain. They're scattered across the body — in the heart, liver, kidneys, and brain. Drugs that hit these receptors seem to carry downstream effects nobody fully saw coming when semaglutide was being built as a diabetes drug. Whether that's a class effect or specific to this molecule is still getting sorted out, but the consistency of the signals across organ systems is hard to wave away.

For people wondering whether they qualify for GLP-1 treatment in the first place, CKD context may be increasingly relevant to that conversation—even though it's not yet an FDA-approved indication.

What to realistically expect if you start

If you have type 2 diabetes and CKD and your doctor prescribes semaglutide, here's what the first few months usually look like.

The dose starts low. Semaglutide kicks off at 0.25 mg weekly and climbs slowly — typically to 0.5 mg after four weeks, then 1.0 mg after another four. FLOW used 1.0 mg, the standard Ozempic maintenance dose, not the higher Wegovy doses.

Nausea is the most common early side effect. It hits roughly 20–30% of people in the first four to six weeks, then usually fades. Smaller meals, easing off high-fat foods, and not lying down right after eating all help. For most people it's manageable. A minority find it bad enough to pause or stop.

eGFR can dip a little when you first start semaglutide, the same way it does with SGLT2 inhibitors. This usually isn't a true decline — it reflects a hemodynamic shift in kidney blood flow — and it tends to settle. Still, flag it with your doctor ahead of time so a short-term eGFR blip on your next lab panel doesn't set off alarms.

The kidney benefits in FLOW took time to build. The trial ran 3.4 years before stopping early. You won't see a dramatic eGFR jump in three months. The goal is a slower rate of decline, measured over years — not a reversal you'll catch in a single lab draw.

Tracking your kidney numbers while on GLP-1

If you're using Blueshot to log your medication, there's a practical case for tracking the numbers your nephrologist follows too — not to replace their monitoring, but to give yourself a clearer view of your own trajectory over time.

The core numbers to know:

• eGFR: Target is stability, or slower-than-expected decline. A rough benchmark is that CKD typically progresses at 1–5 mL/min/1.73m² per year; slower than that on treatment is a win.
• UACR: Anything moving from high toward lower categories is a positive signal.
• HbA1c: Better glucose control typically correlates with slower CKD progression.
• Blood pressure (systolic): Below 130 mmHg is the current target for most people with CKD and diabetes, per ADA/KDIGO guidelines.

Logging your medication timing alongside your labs gives you a long-term picture that's easy to review with your nephrologist, rather than reconstructing your history from memory at each appointment.

FLOW stopped early because the evidence was already clear enough. Semaglutide cut the risk of major kidney events by 24% — dialysis, kidney failure, death from kidney or cardiovascular causes — in people with type 2 diabetes and CKD, with a confidence interval that never touches 1.0.

That result doesn't come stamped with an FDA approval for kidney disease yet. It comes with off-label complexity, prior authorization battles, and a monthly list price that makes plenty of people's eyes water. SGLT2 inhibitors are still the first-line kidney-protective drug for most people, and rightly so — they got there earlier, with clearer regulatory approval.

But the data is out there, it's NEJM-quality, and it's worth a real conversation with your nephrologist or endocrinologist — not a passing mention squeezed into the last two minutes of a visit. If you've watched your eGFR slide for years, FLOW is the most direct evidence available that a GLP-1 drug might bend that line.

So bring the trial to your next appointment. Ask the specific questions. The kidney-damage clock doesn't wait for the FDA to catch up — and you don't get a second pair of these.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app